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Abstract
One of the major obstacles of chemotherapy is that, after repeated treatments, cellular
resistance to the drug appears. The problem is that the tumor cells become resistant not only to the
drugs which have been used during the treatment but also to other drugs which are structurally and
functionally unrelated. This is termed ’multidrug resistance’ (MDR). MDR is frequently associated
with decreased drug accumulation resulting from enhanced drug efflux. This is correlated with the
presence of a membrane protein, P-glycoprotein, which pumps a wide variety of drugs out of cells
thus reducing their toxicity. The search for molecules able to reverse MDR is very important. We
here report that mobile ionophores such as valinomycin, nonactin, nigericin, monensin, calcimycin,
lasalocid inhibit the efflux of anthracycline by P-glycoprotein whereas, channel-forming ionophores
such as gramicidin do not. Cyclosporin which is also a strong Ca2+ chelating agent also inhibits the
P-glycoprotein-mediated efflux of anthracycline.
One of the major obstacles of chemotherapy is that, after repeated treatments, cellular resistance to
the drug appears. It has been estimated that among the one million deaths per year due to cancer in
Europe, 90% of them were influenced by the problem of drug resistance to chemotherapeutic
agents. The problem is that the tumor cells become resistant not only to the drugs which have been
used during the treatment but also to other drugs which are structurally and functionally unrelated.
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This is termed ’muitidrug resistance’ (MDR) [1,2].
Analysis ofMultidnag Transporte.r in Living Cells. Inhibition
ofP-Glycoprotein-MediatedEffltvc ofAnthracyclines bylonophores
MDR is a now well-characterised phenomenon. The mechanisms of MDR are far from been
elucidated and, in fact, modifications of several cellular functions have been observed. Thus, MDR is
frequently associated with decreased drug accumulation resulting from enhanced drug efflux. This
is correlated with the presence of a membrane protein, P-glycoprotein, which pumps a wide variety
of drugs out of cells thus reducing their toxicity [3-7]. This drug efflux is ATP-dependent.
Genetic analysis suggests that P-gp is a member of a family of membrane associated
transport proteins which are involved in multidrug resistance, malarial chloroquine resistance by
Plasmodium falciparum, cystic fibrosis, peptide transport, heavy metal resistance and bacterial
transport processes [8}. P-gp is also present in several normal tissues [9]. However, to date no
naturally occurring substrates have been identified for P-gp.
The mechanism of the transport process is not known for any of the transporters of the ABC
super family, including one reconstituted in artificial vesicles. The hydrolysis of .,TP apparently
provides the energy for drug extrusion from the cell.
Perhaps the most puzzling question related to P-gp function is the unique ability of P-gp to
recognise and transport a great number of apparently unrelated compounds. This transport can be
inhibited by various compounds. It has been suggested that the minimum set of structural and
functional features required for modulator binding to P-gp would be two planar aromatic domains
and a nitrogen atom [101.
To analyse the function of the multidrug transporter in living cells, we have developed a
method with which it is possible to follow the uptake of fluorescent drugs, such as anthracyclines, by
cells, continuously, as incubation of the drug with the cells proceeds [11-13] This method does not
perturb the drug distribution in the various cell compartments and is a simple and rapid technics for
measuring intracellular drug accumulation, membrane transport rates or changes in membrane
transport rates.
In the course of our studies concerning the effect of membrane potential on the uptake and
release of anthracycline derivatives by drug sensitive and resistant cells we were surprised to
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observe that ionophores such as nigericin, valinomycin etc which are currently used to abolish the
transmembrane potential were in fact able to inhibit the P-glycoprotein-mediated efflux of
anthracycline. This lead us to systematically investigate the effect of ionophores on the P-gp-
mediated efflux of 4’-o-tetrahydropyranyl-adriamycin (THP-adriamycin).in resistant K562 (an
erythroleukemia cells line).
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The possibility that some ionophores could modulate multidrug resistance has been
reported. However, considerable confusion exists regarding the mechanism(s) by which
ionophores bring about effects in resistant (and parent) cells: the modulation of adriamycin
resistance in Chinese hamster ovary cells has been reported and the authors concluded that
valinomycin exerts its actions by mechanism(s) other than increasing intracellular accumulation of
drug [14]. Also, Crifo et al. have proposed that the adriamycin toxicity in a adriamycin-resistant
human cancer cell line can be enhanced by very low concentration of valinomycin [15]. Recent
studies using carboxylic ionophores such as monensin and nigericin have indicated that these
agents can modulate anthracycline toxicity apparently by causing an enhancement of anthracycline
accumulation [16,17]. It has also been noticed that the cytotoxic action of drugs as monensin [18]
and nigericin ([19] may be assigned in the decrease cellular ATP levels.
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In order to check what was the action of these ionophores on the P-gp-mediated efflux of
drugs and thus on the intracellular drug accumulation, we have determined the experimental
conditions in which the additions of these ionophores would lead neither to an intracellular pH
modification nor to a plasma membrane potential variation. For this purpose we have used sensitive
cells and checked the effects of ionophores on the intracellular accumulation of THP-adriamycin. In
Na+-containing hepes buffer the addition of nigericin and lasalocid yielded an increase of the drug
accumulation due to a decrease of the intracellular pH (pHi), whereas the addition of monensin
yielded a decrease of the drug accumulation due to an increase of pHi. However, in K+-containing
hepes buffer, these three ionophores are not able to modify PHi and by so far do not yield a
modification of the THP-adriamycin accumulation. The other ionophores that we have tested, i.e.
calcimycin, valinomycin, nonactin, as well as cyclosporin do not yield modification of the THP-
adriamycin accumulation, either in Na+ or K+-containing hepes buffer. We have also checked that
pHi was the same in both sensitive and resistant cells [12] On the other hand the membrane
potential is the same for type of cells and has no effect on the THP-adriamycin "accumulation.
In the case of resistant cells we have observed that the addition of these ionophores lead to
an increase of THP-adriamycin accumulation. For instance, when 106cells/ml are incubated with
llaM THP-adriamycin, the overall concentration of drug bound to the nucleus at the steady state is
(Cn)S=0.54tM and (Cn)R=0.251aM for sensitive and resistant cells respectively.The addition of
ionophore to the resistant cells gives rise to an increase of (Cn)FI. If (Cn)Ri stands for the overall
concentration of drug bound to the nucleus of resistant cells in the presence of the concentration [I]
of ionophore we have the following equation.
(Cn)Fli (Cn)R + [(Cn)S-(Cn)Rl(x
where x is comprised between 0 (in the absence of ionophore) and 1.
Under our experimental conditions, the amount of ionophores required to obtain x=0.5 is
0.31aM (nigericin), 0.41aM (lasalocid), 1.11aM (monensin), 1.21aM (caicimycin), 0.71aM (valinomycin),
0.31aM (nonactin). In the case of cyclosporin ,which is a now a well recognised MDR reverting agent,
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0.31M of product is required to obtained (x=o.5.For a sake of comparison we can add that, under our
experimental conditions, 2M verapamil, the well-known MDR reversing agent, are required to
obtain (=o.5. Under our experimental conditions, gramicidin has no effect on the intracellular
accumulation of THP-adriamycin accumulation. On the other hand, we have checked that all these
ionophores do not lead to a decrease of the intracellular ATP level.
Ionophores are a heterogeneous group of antibiotic which have the common propertiy of
altering membrane permeability towards small inorganic ions. There are two basic types: (a) channel-
forming ionophores (e.g.:gramicidin) that formed water-filled transmembrane channels or pores of
narrow diameter, which permit the movement of ions and small molecules; (b) mobile ionophores
that binds metal ions or organic cations to form lipid soluble complexes, which can then shuttle back
and forth across the cell membrane. The second class can be divided in two groups: those, such as
valinomycin and nonactin, which transport cations as lipid-soluble charged complexes and those,
such as nigericin monensin, lasalocid, calcimycin, which contain a charged carboxyl group and
transports cations as lipid-soluble, electrically neutral complex [20].
Cyclosporin A is not considered as a mobile ionophore however it shared with this class of
compounds a certain number of properties: its a strong metal chelating agent [21], it can affect the
physico-chemical properties of the plasma membrane it has been shown to bind to phospholipid
vesicles ([22] and depolarise cytoplasmic membrane potentials [23]. The first report of a preferential
effect of CsA in resistant versus sensitive tumour cells was by Slater et al. in 1986 [24]. Confusion
exists regarding the mechanism(s) by which cyclosporin A brings about increased drug effects in
resistant (and parent) cells, in some examples, increased effect is apparently associated with
increases in intracellular drug accumulation but, in other examples, this does not appear to be the
case ([25].
Our data clearly established that these ionophores that once in the membrane are
complexed to metal ions are thus either neutral or once positively charged, are able to inhibit the P-
gp -mediated efflux of THP-adriamycin. Cyclosporin A which is also a strong metal chelating agent
has comparable effect.
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